A Phase 3 clinical trial is a large-scale study that tests whether a new treatment actually works better, or more safely, than existing options. It’s the final and most rigorous stage of human testing before a drug or therapy can be submitted for regulatory approval. These trials typically enroll 300 to 3,000 volunteers and run for one to four years, though some extend longer.
What Phase 3 Trials Are Designed to Do
The core purpose of a Phase 3 trial is confirmation. By this point, earlier phases have already established that a treatment is reasonably safe (Phase 1) and shows signs of working (Phase 2). Phase 3 asks the definitive question: does this treatment perform well enough, in a large and diverse group of people, to justify changing how medicine is practiced?
To answer that, Phase 3 trials compare the new treatment against a standard treatment or a placebo. Researchers measure specific outcomes called endpoints. In cancer trials, those endpoints are often survival time or how long a patient lives without their disease getting worse. In infectious disease trials during the COVID-19 pandemic, common endpoints included time to recovery, whether patients needed mechanical ventilation, and in-hospital death rates. The choice of endpoint depends on the disease and what matters most to patients and doctors.
Phase 3 trials also track side effects on a much larger scale than earlier phases. A rare side effect that affects 1 in 1,000 people might never show up in a Phase 2 trial of 200 volunteers. With thousands of participants, Phase 3 trials have the statistical power to catch those rarer problems.
How Phase 3 Differs From Earlier Phases
The clinical trial process is designed like a funnel. Each phase filters out treatments that don’t meet the bar, and the requirements get stricter as you go.
- Phase 1 tests a treatment in a small group (often a few dozen people) primarily to assess safety, dosing, and how the drug behaves in the body. Most participants are healthy volunteers.
- Phase 2 expands to several hundred participants who have the disease or condition. The goal is to see early signs of effectiveness while continuing to monitor safety. These studies often run at a single site and last two to five years.
- Phase 3 scales up dramatically, enrolling hundreds to thousands of participants across multiple locations. Running at many sites isn’t just about speed. It ensures the study population is diverse enough that results apply broadly, not just to one demographic or one hospital’s patient base. These trials often run five to seven years when you include follow-up periods.
A key distinction: Phase 2 results can suggest a treatment looks promising, but they aren’t considered strong enough evidence to change medical practice. Phase 3 results are. A successful Phase 3 trial can directly lead to a new standard of care.
Who Participates and How They’re Protected
Phase 3 participants are people who have the disease or condition the treatment targets. They’re typically divided into groups randomly, with some receiving the new treatment and others receiving the current standard treatment (or a placebo, when no standard exists). This randomization helps ensure that any difference in outcomes is actually caused by the treatment, not by chance or other factors.
Every clinical trial involving human subjects must be reviewed and approved by an Institutional Review Board (IRB) before it begins. An IRB is an independent committee that evaluates whether the study design protects participants’ rights and welfare. This isn’t a one-time check. The IRB conducts continuing reviews at least once a year and must be notified of any changes to the study. If concerns arise about how the trial is being conducted or how consent is being obtained, the board has the authority to audit the process or halt the study entirely.
The Cost of Running a Phase 3 Trial
Phase 3 trials are the most expensive stage of drug development by a wide margin. Estimates of the median cost range from $19 million to $200 million per trial, depending on the disease area, the number of participants, and how the costs are calculated. One widely cited estimate puts the median at $127 million. Per-patient costs range from roughly $17,500 to $62,000.
These numbers help explain why drug development is so expensive overall, and why pharmaceutical companies are selective about which treatments they advance to Phase 3. The financial risk is enormous, because most drugs that enter Phase 3 still don’t make it to approval.
Success Rates and What Happens After
Only about 25 to 30 percent of drugs that enter Phase 1 testing will eventually pass through all three phases. Looking at Phase 3 specifically, roughly 24 percent of drugs that begin Phase 3 trials go on to receive approval. That means about three out of four treatments fail at this late stage, often after years of testing and hundreds of millions of dollars in investment. For orphan drugs (treatments for rare diseases), the success rate drops further to about 10 percent.
When a Phase 3 trial produces positive results, the data becomes the backbone of a New Drug Application submitted to the FDA. This application tells the drug’s complete story: animal study results, clinical trial data from all phases, how the drug is manufactured and packaged, and how it behaves in the body. FDA reviewers use this information to decide whether the treatment is safe and effective for its intended use, and whether its benefits outweigh its risks.
The review process itself can take additional months to over a year. Some treatments receive priority or accelerated review if they address serious conditions with unmet medical needs, but the Phase 3 data remains the most critical evidence in the decision.
Why Some Phase 3 Trials Make Headlines
Phase 3 results often generate significant public attention because they represent the moment a treatment either proves itself or doesn’t. When you see a news headline saying a new cancer drug “showed positive results in a late-stage trial,” that’s a Phase 3 result. These announcements can move pharmaceutical stock prices, shape treatment guidelines, and give patients with serious illnesses a concrete reason for hope or disappointment.
It’s worth keeping context in mind when reading these headlines. A treatment can meet its primary endpoint and still show only a modest improvement over existing options. The size of the benefit, the severity of side effects, and how the results apply to different patient populations all matter. Phase 3 data is the gold standard of clinical evidence, but the full picture only becomes clear once regulators, doctors, and patients weigh the tradeoffs.